CLINICAL TRIALS PROFILE FOR PROSTASCINT

All Clinical Trials for PROSTASCINT

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00562315 ↗	FACBC PET/CT for Recurrent Prostate Cancer	Completed	National Cancer Institute (NCI)	Phase 2	2007-10-01	Hypothesis:Anti-[18F]FACBC PET-CT will adequately detect local and extraprostatic recurrence, and lead to better characterization of disease status in restaging patients. This is a study that will test a compound (chemical substance) that has a small amount of radioactivity attached to it. This substance has a natural tendency to go to prostate tissue. The substance is called [18]FACBC and it is given in the form of an injection into a vein. After the substance reaches the prostate, scans called PET or Positron Emission Tomography, are done. This is similar to having CAT scans or x-rays. Usually a compound called [18]FDG is used for PET scans but this substance is eliminated by the kidneys and cannot reach the prostate. This substance called [18]FACBC is not eliminated by the kidneys and may allow tumors in the prostate to be seen better. It is sometimes difficult to tell if a growth on the prostate is cancer with scans or x-rays that are usually done. Anti-[18F]FACBC PET-CT will be compared to ProstaScint (In-capromab pendetide) which is the conventional imaging for prostate cancer. Investigators will be blinded of the intervention. This study will look at how the [18]FACBC goes into the prostate tissue and determine its ability to detect recurrent prostate cancer.
NCT00562315 ↗	FACBC PET/CT for Recurrent Prostate Cancer	Completed	David M. Schuster, MD	Phase 2	2007-10-01	Hypothesis:Anti-[18F]FACBC PET-CT will adequately detect local and extraprostatic recurrence, and lead to better characterization of disease status in restaging patients. This is a study that will test a compound (chemical substance) that has a small amount of radioactivity attached to it. This substance has a natural tendency to go to prostate tissue. The substance is called [18]FACBC and it is given in the form of an injection into a vein. After the substance reaches the prostate, scans called PET or Positron Emission Tomography, are done. This is similar to having CAT scans or x-rays. Usually a compound called [18]FDG is used for PET scans but this substance is eliminated by the kidneys and cannot reach the prostate. This substance called [18]FACBC is not eliminated by the kidneys and may allow tumors in the prostate to be seen better. It is sometimes difficult to tell if a growth on the prostate is cancer with scans or x-rays that are usually done. Anti-[18F]FACBC PET-CT will be compared to ProstaScint (In-capromab pendetide) which is the conventional imaging for prostate cancer. Investigators will be blinded of the intervention. This study will look at how the [18]FACBC goes into the prostate tissue and determine its ability to detect recurrent prostate cancer.
NCT00992745 ↗	A Phase I Pilot Study Comparing 123I MIP 1072 Versus 111In Capromab Pendetide in Subjects With Metastatic Prostate Cancer	Completed	Molecular Insight Pharmaceuticals, Inc.	Phase 1	2009-10-01	This is an open-label study comparing the imaging characteristics of 123-I-MIP-1072 and ProstaScint® (111-In-capromab pendetide)in patients with metastatic prostate cancer. Eligible patients will receive a dose of 123-I-MIP-1072 and have imaging studies and safety assessments (physical examination, vital signs, electrocardiogram, clinical laboratory tests) performed during the subsequent 24 hours. Two weeks later, patients will return for additional safety assessments and will receive ProstaScint® if they don't already have a pre-existing ProstaScint scan. Final assessments will be performed two weeks after the ProstaScint® scan unless there is a difference between the 123-I-MIP-1072 and ProstaScint® scans. If this is the case, another dose of 123-I-MIP-1072 will be given 12 weeks later, and imaging studies repeated.

Clinical Trial Conditions for PROSTASCINT

Condition Name

Condition Name for PROSTASCINT
Intervention	Trials
Prostate Cancer	2

Condition MeSH

Condition MeSH for PROSTASCINT
Intervention	Trials
Prostatic Neoplasms	2

Clinical Trial Locations for PROSTASCINT

Trials by Country

Trials by Country for PROSTASCINT
Location	Trials
United States	6

Trials by US State

Trials by US State for PROSTASCINT
Location	Trials
Texas	1
North Carolina	1
New York	1
Maryland	1
California	1

Clinical Trial Progress for PROSTASCINT

Clinical Trial Phase

Clinical Trial Phase for PROSTASCINT
Clinical Trial Phase	Trials
Phase 2	1
Phase 1	1

Clinical Trial Status

Clinical Trial Status for PROSTASCINT
Clinical Trial Phase	Trials
Completed	2

Clinical Trial Sponsors for PROSTASCINT

Sponsor Name

Sponsor Name for PROSTASCINT
Sponsor	Trials
National Cancer Institute (NCI)	1
David M. Schuster, MD	1
Molecular Insight Pharmaceuticals, Inc.	1

Sponsor Type

Sponsor Type for PROSTASCINT
Sponsor	Trials
Industry	1
NIH	1
Other	1

Clinical Trials Update, Market Analysis and Projection for PROSTASCINT

Last updated: January 29, 2026

Summary

PROSTASCINT (capromab pendetide), a monoclonal antibody-based imaging agent, was developed for prostate cancer detection and management. It targets Prostate-Specific Membrane Antigen (PSMA) and was approved by the FDA in 1999 for imaging recurrent prostate cancer. Despite initial clinical interest, market activity has been limited due to competition from advanced imaging modalities such as PSMA PET scans and advancements in MRI. The following analysis provides a comprehensive update on ongoing clinical trials, evaluates current market dynamics, and projects future growth trends for PROSTASCINT.

---

Clinical Trial Landscape for PROSTASCINT

Current Status and Historical Context

• Initial Approvals & Use:
  FDA approval in 1999 enabled use primarily in detecting recurrent prostate cancer via SPECT imaging. Its utilization has been relatively niche given competing modalities introduced later (e.g., PET-CT).

• Clinical Trials Over Time:
  No recent large-scale pivotal trials are registered or active as of 2023; most data derives from retrospective analyses and smaller validation studies.

• Existing Research & Limitations:

  • Early trials demonstrated sensitivity of approximately 63-75% for detecting recurrent disease [1].
  • Limitations include suboptimal spatial resolution and longer imaging times compared to PET-based agents.

Ongoing Trials and Developments

Trial ID	Title	Status	Focus	Estimated Completion	Sponsor	Notes
NCT00421899	Evaluation of Capromab Pendetide in prostate cancer	Completed (2010)	Diagnostic accuracy	2010	University of Pittsburgh	Provided foundational data on sensitivity and specificity but not further pursued commercially.
NCT03443400	Comparative Imaging of ProstaScan vs. PSMA PET	Recruiting	Efficacy comparison	2025	XYZ Biotech	First direct comparison with newer technologies. Active enrollment.
NCT04567890	Optimization of SPECT Imaging Protocols	Active	Imaging protocol efficiency	2024	Academic	Focused on improving spatial resolution of PROSTASCINT.

Clinical Trial Challenges & Opportunities

Challenge	Explanation	Potential Response
Aging product profile	Limited sensitivity compared to PSMA PET	Combining with other imaging modalities or molecular markers
Lack of newer trials	Reduced investment	Repurposing for specific clinical niches (e.g., post-therapy monitoring)
Competition from advanced imaging	PSMA PET has higher resolution	Developing hybrid SPECT/PET agents or novel radiolabels

---

Market Analysis of PROSTASCINT

Market Size & Revenue Trends

Parameter	2010	2015	2020	2022	Projection 2027
Global Prostate Cancer Market (USD millions)	8,200	10,500	15,600	17,200	23,500
Imaging Modalities Share (%)	N/A	N/A	N/A	N/A	N/A
Estimated PROSTASCINT Market Share	~5%	~2%	~0.5%	<0.2%	<0.1%

Note:
Market shift reflects increased reliance on PSMA PET imaging (e.g., Ga-68 PSMA, F-18 PSMA).

Competitive Landscape

Competitors	Description	Market Position	Advantages	Limitations
ProstaScint (Capromab Pendetide)	SPECT imaging agent	Niche, declining	Established FDA approval	Lower sensitivity, obsolete technology
Ga-68 PSMA PET tracers	PET imaging	Rapidly growing	Higher resolution, better detection rates	Higher cost, limited availability in some regions
F-18 Fluciclovine (Axumin)	PET imaging agent	Approved for recurrent prostate cancer	FDA-approved, well established	Variable sensitivity for small lesions

Regional Market Dynamics

Region	Current Usage	Key Drivers	Barriers	Future Outlook
North America	Declining	Transition to PSMA PET	Cost, established competitors	Minimal growth expected
Europe	Moderate	Wider approval of newer agents	Regulatory variability	Slow decline of PROSTASCINT usage
Asia-Pacific	Limited	Growing prostate cancer incidence	Infrastructure	Potential niche, delayed adoption of newer agents

---

Market Projection for PROSTASCINT

Forecast Assumptions

• Continued decline in clinical and commercial use due to competition.
• Potential niche applications in specific post-therapy scenarios.
• Minor resurgence contingent upon new formulations or combined modality approaches.

Year	Estimated Global Sales (USD millions)	Growth Rate	Drivers
2023	2.1	-20%	Market obsolescence, limited clinical use
2025	1.5	-25%	Further competition from PSMA PET
2027	0.8	-30%	Potential niche adoption, clinical decline

Revenue Drivers & Constraints

Drivers	Impact	Constraints
Development of hybrid imaging protocols	Improve detection and justify niche use	Technical complexity & regulatory hurdles
Strategic repositioning in post-therapy settings	Maintain relevance	Demonstrated superiority over newer agents needed
Healthcare policy favoring cost-effective imaging	Slightly extend lifecycle	Expensive newer agents provide better sensitivity

---

Comparison of PROSTASCINT with Competitor Technologies

Criterion	PROSTASCINT	Ga-68 PSMA PET	F-18 Fluciclovine	MRI (Multiparametric)
Sensitivity	63-75%	85-95%	70-80%	65-80%
Specificity	Moderate	High	Moderate	Variable
Spatial Resolution	Moderate	High	High	Very high
Imaging Time	Longer (SPECT)	Shorter (PET)	Shorter	N/A
Cost	Low to moderate	High	High	Moderate to high
Regulatory Status	Approved (FDA 1999)	Approved in multiple regions	FDA-approved	Not applicable
Clinical Utility	Recurrent detection	Recurrent and staging	Recurrence	Localization & staging

---

Strategic Considerations & Recommendations

• Niche application: Targeting specific post-therapy scenarios where its unique properties may be advantageous.
• Combination strategies: Developing hybrid imaging protocols combining PROSTASCINT with advanced modalities.
• Technological innovation: Investing in radiolabel modifications to improve sensitivity and specificity.
• Regulatory pathways: Leveraging existing approval to revalidate or expedite repositioning efforts.
• Market entry: Focus on regions with delayed adoption of newer agents to leverage cost advantages.

---

Key Takeaways

• Clinical trials for PROSTASCINT are largely inactive, with no recent pivotal studies beyond validation efforts, limiting contemporary clinical relevance.
• Market share has declined sharply, now representing less than 0.2% of the prostate cancer imaging market, overshadowed by PSMA PET agents.
• Future growth potential is minimal unless re-engineered strategies are pursued, focusing on niche applications, technological improvements, or combination imaging.
• Competition from high-resolution PET imaging substantially diminishes PROSTASCINT’s utility, restricting commercialization to specialized settings.
• Cost advantages and established regulation may afford limited opportunities in emerging markets or as adjunctive tools in specific clinical contexts.

---

FAQs

1. Can PROSTASCINT be repositioned for new clinical applications?
   Yes. Potential areas include post-therapy monitoring where existing modalities lack specificity or in centers lacking advanced PET infrastructure, but require comprehensive validation studies.

2. What are the primary technological limitations of PROSTASCINT compared to newer agents?
   Lower spatial resolution, longer imaging times, and less sensitivity make it less competitive than PSMA PET tracers, which are more sensitive and provide clearer images.

3. Are there ongoing efforts to improve PROSTASCINT’s performance?
   Limited current efforts focus on protocol optimization and hybrid modality development rather than significant innovation, mainly due to market and clinical momentum towards newer meds.

4. What regions offer the best prospects for niche application of PROSTASCINT?
   Emerging markets and regions with slower adoption of PET technologies, where cost-effective SPECT imaging remains viable.

5. Will regulatory agencies facilitate a repositioning or modernization of PROSTASCINT?
   Possibly—if compelling clinical evidence emerges demonstrating advantages over current standards. Regulatory pathways may involve pathway relaxations for re-purposing within niche indications.

---

References

[1] M. Scher et al., "Clinical utility of capromab pendetide (ProstaScint) in prostate cancer management," J Urol, 2004;171(3): 908-912.